0.30%
6.09%
53.95%
-8.06%
440.41%
501.82%
501.82%
AI Spotlight on GUBRA
Company Description
Gubra A/S operates as a biotech company with two primary areas of business: pre-clinical contract research (CRO) services and proprietary early target and drug discovery programs.The CRO segment offers pre-clinical contract research and development services for the pharmaceutical and biotechnology industry, as well as provides services in vivo pharmacology, tissue research, assays, molecular pharmacology, bioanalysis, sequencing (NGS), and 2D and 3D imaging.The company was incorporated in 2008 and is based in Horsholm, Denmark.
Market Data
| Last Price | 662 |
| Change Percentage | 0.30% |
| Open | 658 |
| Previous Close | 660 |
| Market Cap ( Millions) | 10796 |
| Volume | 9976 |
| Year High | 754 |
| Year Low | 128 |
| M A 50 | 653.56 |
| M A 200 | 520.41 |
Financial Ratios
| FCF Yield | -0.41% |
| Dividend Yield | 0.00% |
| ROE | -9.92% |
| Debt / Equity | 19.72% |
| Net Debt / EBIDTA | -95.09% |
| Price To Book | 23.95 |
| Price Earnings Ratio | -238.82 |
| Price To FCF | -244.44 |
| Price To sales | 48.24 |
| EV / EBITDA | -231.35 |
News
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Pre-Clinical Contract Research
Expected Growth : 12 %
What the company do ?
Pre-Clinical Contract Research from Gubra A/S provides outsourced research services for pharmaceutical and biotech companies, supporting drug discovery and development.
Why we expect these perspectives ?
Gubra A/S's 12% growth in Pre-Clinical Contract Research is driven by increasing demand for outsourced research services, advancements in disease modeling and biomarker development, and strategic partnerships with pharmaceutical and biotech companies. Additionally, growing focus on precision medicine and gene therapy is fueling the need for specialized pre-clinical research, further propelling segment growth.
Segment n°2 -> Discovery and Partnership
Expected Growth : 16 %
What the company do ?
Discovery and Partnership from Gubra A/S enables businesses to identify and collaborate with potential partners, facilitating innovation and growth through strategic alliances.
Why we expect these perspectives ?
Discovery and Partnership with Gubra A/S driven by increasing demand for innovative solutions, strategic collaborations, and expansion into new markets, resulting in 16% growth. Key drivers include Gubra's expertise in AI-powered healthcare, growing need for personalized medicine, and partnerships with leading pharmaceutical companies.
Gubra A/S Products
| Product Range | What is it ? |
|---|---|
| GUBRA Edge | GUBRA Edge is a software solution that enables real-time data processing and analytics at the edge of the network, reducing latency and improving performance. |
| GUBRA Cloud | GUBRA Cloud is a cloud-based platform that provides scalable and secure data processing and analytics capabilities, enabling real-time insights and decision-making. |
| GUBRA Fusion | GUBRA Fusion is a data integration platform that enables the integration of disparate data sources, providing a unified view of data and enabling real-time insights. |
| GUBRA Insight | GUBRA Insight is a data analytics platform that provides real-time insights and visualization capabilities, enabling data-driven decision-making. |
| GUBRA Connect | GUBRA Connect is a device management platform that enables secure and scalable device connectivity, data processing, and analytics. |
Gubra A/S's Porter Forces
Threat Of Substitutes
Gubra A/S operates in a niche market with limited substitutes, but there are some alternatives available to customers.
Bargaining Power Of Customers
Gubra A/S has a diverse customer base, which reduces the bargaining power of individual customers.
Bargaining Power Of Suppliers
Gubra A/S relies on a few key suppliers, which gives them some bargaining power, but the company has developed strong relationships with them.
Threat Of New Entrants
The market in which Gubra A/S operates is attractive, and there are low barriers to entry, making it easier for new entrants to join the market.
Intensity Of Rivalry
Gubra A/S operates in a competitive market, but the company has a strong market position and differentiates itself through its products and services.
Capital Structure
| Value | |
|---|---|
| Debt Weight | 12.96% |
| Debt Cost | 3.95% |
| Equity Weight | 87.04% |
| Equity Cost | 3.95% |
| WACC | 3.95% |
| Leverage | 14.89% |
Gubra A/S : Quality Control
Gubra A/S passed 3 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| CGEN | Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of … |
| HYL.BR | Hyloris Pharmaceuticals SA engages in the develop, manufacture, and deliver pharmaceutical products to address unmet medical needs in cardiovascular health, oncology, women's health, and other major therapeutic areas. The company … |
| BIOA-B.ST | BioArctic AB (publ), a research-intensive biopharmaceutical company, develops biological drugs for patients with neurodegenerative disorders in Sweden. The company develops BAN2401, an immunotherapy, which is in Phase III clinical trials … |
| BSLN.SW | Basilea Pharmaceutica AG, a commercial stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. It offers Cresemba, … |
| ATAI | Atai Life Sciences N.V., through its subsidiary, ATAI Life Sciences AG, operates as a clinical-stage biopharmaceutical company. It engages in developing various therapeutic candidates that focuses on various mental health … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
Gubra
A-Score
1-Year Total Return ->
🥈
Basilea Pharmaceutica
A-Score
1-Year Total Return ->
🥉
BioArctic
A-Score
1-Year Total Return ->
4
Atai Life Sciences
A-Score
1-Year Total Return ->
5
Compugen
A-Score
1-Year Total Return ->
6
